Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

BMS Streamlines Pipeline, Removes Two Clinical Programs Amid Leadership Changes

BMS Streamlines Pipeline, Removes Two Clinical Programs Amid Leadership Changes

Bristol Myers Squibb (BMS) has announced the removal of two clinical programs from its pipeline, signaling a strategic shift in its research and development focus. The move comes as part of the company's ongoing cost-saving initiative and coincides with recent leadership transitions.

NoahAI News10/31/2025
Inflammation Biotech Evommune Sets Sights on NYSE with Upcoming IPO

Inflammation Biotech Evommune Sets Sights on NYSE with Upcoming IPO

Evommune, a California-based biotech company specializing in inflammation treatments, has announced its plans to go public on the New York Stock Exchange. The company aims to price its initial public offering (IPO) between $15 and $17 per share, with the ticker symbol "EVMN."

NoahAI News10/31/2025
Biogen's Resilient Performance Drives Updated Sales Outlook Amid New Product Momentum

Biogen's Resilient Performance Drives Updated Sales Outlook Amid New Product Momentum

Biogen, a leading player in the pharmaceutical industry, has raised its sales forecast for 2025, citing the robust performance of its legacy multiple sclerosis (MS) franchise and the growing traction of its new product launches. The company's third-quarter results have exceeded expectations, signaling a positive trajectory after years of declining sales.

NoahAI News10/31/2025
Eli Lilly Invests $1.2B in Puerto Rico Facility, Boosting Oral Drug Production Capacity

Eli Lilly Invests $1.2B in Puerto Rico Facility, Boosting Oral Drug Production Capacity

Eli Lilly and Company has announced a significant $1.2 billion investment to expand and modernize its manufacturing complex in Carolina, Puerto Rico. This move is part of the company's broader strategy to enhance its domestic production capabilities, particularly for oral medications, including the highly anticipated GLP-1 pill orforglipron.

NoahAI News10/31/2025
Kyverna's CAR T Therapy Shows Promising Results in Myasthenia Gravis, Signaling Shift in Autoimmune Treatment

Kyverna's CAR T Therapy Shows Promising Results in Myasthenia Gravis, Signaling Shift in Autoimmune Treatment

Kyverna Therapeutics has reported groundbreaking results from its Phase II study of KYV-101, a CAR T cell therapy for generalized myasthenia gravis (gMG), potentially revolutionizing treatment approaches for autoimmune diseases.In a significant development for the field of autoimmune disorders, Kyverna Therapeutics announced a 100% response rate in patients with gMG treated with KYV-101. The Phase II portion of the KYSA-6 study, involving six patients with moderate to severe gMG who had previously failed immunosuppressant therapies, demonstrated clinically meaningful improvements in activities of daily living at 36 weeks post-treatment.

NoahAI News10/31/2025
FDA Places Clinical Hold on Intellia's Gene Therapy Studies Due to Liver Toxicity

FDA Places Clinical Hold on Intellia's Gene Therapy Studies Due to Liver Toxicity

The U.S. Food and Drug Administration (FDA) has officially placed two of Intellia Therapeutics' Phase III studies under clinical hold following reports of life-threatening liver side effects in a patient. This regulatory action comes just days after Intellia voluntarily paused enrollment and dosing in the same trials.

NoahAI News10/31/2025
Novo Nordisk Challenges Pfizer with $8.5B Bid for Obesity Biotech Metsera

Novo Nordisk Challenges Pfizer with $8.5B Bid for Obesity Biotech Metsera

In a surprising turn of events, Novo Nordisk has launched an unsolicited $8.5 billion bid to acquire obesity drug developer Metsera, challenging Pfizer's previously announced $7.27 billion deal. This move has ignited a fierce bidding war between two pharmaceutical giants, highlighting the industry's growing focus on the lucrative obesity treatment market.

NoahAI News10/31/2025
Lilly's Obesity Drug Zepbound Drives Record-Breaking Sales, Reshaping Pharmaceutical Landscape

Lilly's Obesity Drug Zepbound Drives Record-Breaking Sales, Reshaping Pharmaceutical Landscape

Eli Lilly's groundbreaking obesity and diabetes medication, tirzepatide, has catapulted the company to new heights, becoming the world's best-selling drug and prompting a significant upward revision in the pharmaceutical giant's financial forecasts. The drug's success underscores a pivotal shift in the industry, with obesity treatments emerging as a dominant force in the market.

NoahAI News10/31/2025
FDA Places Clinical Hold on Intellia's CRISPR Trials Following Serious Liver Safety Event

FDA Places Clinical Hold on Intellia's CRISPR Trials Following Serious Liver Safety Event

Intellia Therapeutics has encountered a significant setback in its late-stage clinical trials for a CRISPR-based gene therapy targeting transthyretin amyloidosis (ATTR). The U.S. Food and Drug Administration (FDA) has officially placed a clinical hold on two Phase 3 trials of nexiguran ziclumeran (nex-z) following a serious liver safety incident that led to patient hospitalization.

NoahAI News10/31/2025
Merck's Capvaxive Shows Strong Growth Amid Challenging Vaccine Market

Merck's Capvaxive Shows Strong Growth Amid Challenging Vaccine Market

Merck's new adult pneumococcal vaccine, Capvaxive, has demonstrated impressive sales growth in its third quarter, bucking the trend of declining vaccine revenues across the pharmaceutical industry. This development comes as other major vaccine manufacturers face headwinds in their vaccine divisions.

NoahAI News10/31/2025
BMS' Cobenfy Shows Steady Growth in Schizophrenia, Eyes Expansion into Alzheimer's

BMS' Cobenfy Shows Steady Growth in Schizophrenia, Eyes Expansion into Alzheimer's

Bristol Myers Squibb's (BMS) novel schizophrenia medication, Cobenfy, has completed its first year on the market with sales figures meeting expectations, though investors remain cautious about its future trajectory. Meanwhile, the company is navigating a complex policy landscape and preparing for potential expansion into new indications.

NoahAI News10/31/2025
Zimmer Biomet Secures FDA Breakthrough Status for Innovative Anti-Infection Hip Implant Technology

Zimmer Biomet Secures FDA Breakthrough Status for Innovative Anti-Infection Hip Implant Technology

Zimmer Biomet, a leading medical device manufacturer, has achieved a significant milestone in its efforts to combat post-surgical infections in joint replacements. The company announced on Tuesday that it has received breakthrough device status from the U.S. Food and Drug Administration (FDA) for its iodine-treated total hip replacement system.

NoahAI News10/31/2025
«1234...67»